| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TUBERCULOSIS |
1 Ministerio de Salud, Lima, Perú
2 Division of Social Medicine and Health Inequalities, Brigham and Women’s Hospital, Boston, Massachusetts, USA
3 Socios en Salud, Lima, Peru
Correspondence to:
Correspondence to:
Dr Jennifer Furin
Brigham and Women’s Hospital, Division of Social Medicine and Health Inequalities, 1620 Tremont Street, Third Floor, Boston, Massachusetts 02120, USA; jfurin{at}partners.org
Background: While most patients with tuberculosis (TB) can be successfully treated using short-course medical chemotherapy, thoracic surgery is an important adjunctive strategy for many patients with drug-resistant disease. The need for physical, technical and financial resources presents a potential challenge to implementing surgery as a component of treatment for multidrug-resistant TB (MDR-TB) in resource-poor settings. However, a cohort of patients with severe MDR-TB in Lima, Peru underwent surgery as part of their treatment.
Methods: 121 patients underwent pulmonary surgery for drug-resistant tuberculosis between May 1999 and January 2004. Surgery was performed by a team of thoracic surgeons under the Ministry of Health. Patient demographic data, clinical characteristics, surgical procedures and surgical outcomes were studied.
Results: Most of the patients had failed multiple TB regimens and were resistant to a median of seven drugs. The median time of follow-up after surgery was 33 months. 79.3% of patients were culture-positive before surgery, and sustained culture-negative status among survivors was achieved in 74.8% of patients. 63% of those followed up for at least 6 months after surgery were either cured or probably cured. Postoperative complications, observed in 22.6% of patients, were associated with preoperative haemoptysis, vital capacity <50% and low forced expiratory volume in 1 s.
Conclusions: This is one of the largest cohorts with MDR-TB to be treated with surgery, and the first from a resource-poor country. Although surgery is not often considered an option for patients in resource-poor settings, the findings of this study support the argument that adjunctive surgery should be considered an integral component of MDR-TB treatment programmes, even in poor countries such as Peru.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s; MDR-TB, multidrug-resistant tuberculosis
Relevant Article
Thorax 2007 62: 377.
This article has been cited by other articles:
|
|
 |
|
  Y. Shiraishi, N. Katsuragi, H. Kita, M. Toishi, and T. Onda Experience with pulmonary resection for extensively drug-resistant tuberculosis Interactive CardioVascular and Thoracic Surgery, December 1, 2008; 7(6): 1075 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, H. Lin, and G. Jiang Pulmonary Resection in the Treatment of Multidrug-Resistant Tuberculosis: A Retrospective Study of 56 Cases Ann. Thorac. Surg., November 1, 2008; 86(5): 1640 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Mitnick, S. S. Shin, K. J. Seung, M. L. Rich, S. S. Atwood, J. J. Furin, G. M. Fitzmaurice, F. A. Alcantara Viru, S. C. Appleton, J. N. Bayona, et al. Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N. Engl. J. Med., August 7, 2008; 359(6): 563 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Yew and C. C. Leung Update in Tuberculosis 2007 Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 479 - 485. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
